STAT20h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Acsh.org21h
Chaos in the Courts: Updates and Insights, and How to Store your Valsartan
Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...
BioSpace22h
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
BioPharma Dive2d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Bloomberg L.P.3d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Federal law could prevent your 23andMe data deletion, but you should still try
Some state laws require genetic data to be stored for a period of years, but it's worth requesting 23AndMe deletion now — ...
Terry Smith’s £23bn fund falls out of favour after Magnificent Seven misstep
Fundsmith Equity fell off Interactive Investor's most-bought list as tech funds begin to drop in popularity among retail ...
London South East14d
LONDON BROKER RATINGS: Deutsche cuts Smith & Nephew; Shore lifts Asos
pence - 'neutral' LBBW cuts GSK price target to 1,650 (1,750) pence - 'buy' Deutsche Bank cuts Smith & Nephew to 'hold' (buy) - price target 1,250 (1,350) pence Barclays cuts Smith & Nephew price ...